UK
Health
Our health and the challenges healthcare systems face are changing. Patients have increasingly complex health needs due to multimorbidity, and they experience large inequalities in healthcare outcomes. Meanwhile, the assessment of medicines and corresponding payment mechanisms do not reflect the true value that good health brings to healthcare systems and society at large.
With our innovative and market-leading analytics, we aim to enable the transition of health systems globally from importers of illness to exporters of health by interpreting value between patients, manufacturers of medicines, payers, and other key stakeholders.
Shifting health systems from importers of illness to exporters of health
Combining strategic vision with innovative health analytics
Our global team partners with clients in the life sciences and healthcare industries, bringing together strategic vision and market-leading health analytics to drive three critical shifts:
- Moving from a single-disease focus to a holistic view of healthcare needs by uncovering increasingly complex, multimorbid, unmet patient needs, guiding targeted action, and advancing health equity.
- A broader view of the value of medicines and health: realigning how Health Technology Assessment organizations and payers value medicines, and the value of health to patients, populations, and economies.
- Improving health equity by embedding consideration of inequalities across the medicine life cycle.
Delivering integrated insights that drive maximum value
We bring together expertise across our service areas to deliver integrated insights that create the greatest value for our clients. We support organizations throughout the entire innovation lifecycle by:
-
Transforming real-world healthcare data into actionable insights that guide evidence-based decisions for providers, payers, patients, and policymakers from national institutions like the National Institutes of Health (NIH) and Centers for Medicare & Medicaid Services (CMS) to local care teams.
-
Applying scientific rigor to evaluate the economic and clinical value of healthcare interventions, enabling faster and broader patient access.
-
Developing holistic strategies for global market access and real-world evidence to drive commercial success.
-
Accelerating US access with value-based, evidence-driven solutions built on deep clinical insight and strategic consulting.
-
Creating integrated, compelling visual analytics, powered by AI to support engagement with medical, scientific, and policy leaders.
-
Leveraging large-scale human omics data and advanced analytics to increase the speed and cost-efficiency of drug development.
At LCP, we’re more than a service provider - we’re your strategic thought partner
We partner with clients from proposal to delivery, with senior experts providing hands-on project leadership across service areas. Our leadership experience in science, medicine, consulting, pharmaceuticals, and policy combined with strong partnerships with key decision-makers and state-of-the-art technology, methods, and expertise enables us to deliver insights that address the challenges of tomorrow.
Contact us to learn how we can bring clarity and insight in today’s increasingly complex life sciences and healthcare environment.
Until now there has been limited research on the impact of multi and comorbidities across different patient groups and how this progresses during the course of the disease. This study has highlighted the large variations in clinical need within the patient group.
Programme director, Data and Real World Evidence National Institute for Health and Care Excellence (NICE), UK organization providing guidance and advice to improve health and social care
Explore our health services
Explore our focus areas
Medicines Nexus™
Prescription analytics platform
Our innovative prescription analytics platform delivering cutting-edge insights into the medicines market.
Featured insights
Featured press
Reflections on three years as Chair of the Royal Society for Public Health – Dr Jonathan Pearson-Stuttard
Head of LCP Health, Dr Jonathan Pearson-Stuttard has finished his three-year tenure as Head of the UK's Royal Society for Public Health.
Dr Jonathan Pearson-Stuttard receives lifetime Honorary Fellowship from the Royal Society for Public Health
Dr Jonathan Pearson-Stuttard, Head of LCP Health, has been recognized by the UK's RSPH for his role in shaping public health in the UK and around the world.
LCP Health partners with COTA to advance the use of US RWD to support HTA decision making internationally
LCP Health is partnering with COTA to explore how US real-world data (RWD) can support health technology assessments (HTA) in the United Kingdom (UK) and European Union (EU).
Record performance for LCP reflects commitment to client outcomes, innovation and long-term focus
LCP has announced another successful year, posting record income of £254 million during the financial year 2025/26.
Get in touch
Contact us to learn more about how we can provide clarity and insight in today’s increasingly complex life sciences and healthcare environment.
